A Role for Single Agent TKI Therapies in Treating Renal Cell Carcinoma

Oncologists debate whether TKI monotherapy has a place in renal cell carcinoma treatment after the CLEAR trial.

Related Videos
Experts on HCC
Experts on urothelial carcinoma
Experts on urothelial carcinoma
Experts on urothelial carcinoma
Experts on urothelia carcinoma
Experts on urothelial cancer
Experts on urothelial carcinoma
Experts on urothelial carcinoma
Experts on urothelial carcinoma
Related Content